title: Efficacy of S-1 for patients with peritoneal metastasis of gastric cancer.
abstract: BACKGROUND
  This study was designed to examine the efficacy and compliance of S-1 for the patients with peritoneal metastasis of gastric cancer.
  
  
  METHODS
  Sixteen consecutive patients with peritoneal metastasis of gastric cancer were treated with S-1. Their survival was compared with that of the historical control group (25 patients). Thymidylate synthase, dihydropyrimidine dehydrogenase, thymidine phosphorylase and orotate phosphoribosyl transferase mRNA expression in the tumor were evaluated.
  
  
  RESULTS
  The median survival time of S-1-treated patients was 550 days, which was significantly longer than that of the historical control group (215 days). We elucidated some factors to prolong the survival of the patients treated with S-1 for peritoneal metastasis: peritoneal metastasis without other distant metastases, the combination of S-1 treatment and gastrectomy, and low expression of thymidine phosphorylase mRNA in primary tumors.
  
  
  CONCLUSIONS
  S-1 showed a surprisingly long-term survival with minimum toxicity in patients with peritoneal metastasis of gastric cancer.
authors.affiliation: Department of Surgery, Shinshu University School of Medicine, Matsumoto, Japan.
authors.forename: Satoshi
authors.initials: S
authors.lastname: Ishizone
authors.forename: Fukuto
authors.initials: F
authors.lastname: Maruta
authors.forename: Hiroyasu
authors.initials: H
authors.lastname: Saito
authors.forename: Naohiko
authors.initials: N
authors.lastname: Koide
authors.forename: Atsushi
authors.initials: A
authors.lastname: Sugiyama
authors.forename: Jun
authors.initials: J
authors.lastname: Nakayama
authors.forename: Shinichi
authors.initials: S
authors.lastname: Miyagawa
mesh_terms: D000328:Adult; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000378:metabolism; D042943:Dihydrouracil Dehydrogenase (NADP) / Q000378:metabolism; D004338:Drug Combinations; D005260:Female; D005743:Gastrectomy; D006801:Humans; D007414:Intestinal Neoplasms / Q000473:pathology; D008113:Liver Neoplasms / Q000556:secondary; D008175:Lung Neoplasms / Q000556:secondary; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009962:Orotate Phosphoribosyltransferase / Q000378:metabolism; D010094:Oxonic Acid / Q000009:adverse effects / Q000627:therapeutic use*; D010349:Patient Compliance; D010534:Peritoneal Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000401:mortality / Q000556:secondary*; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000401:mortality / Q000473:pathology / Q000601:surgery; D015996:Survival Rate; D005641:Tegafur / Q000009:adverse effects / Q000627:therapeutic use*; D013939:Thymidine Phosphorylase / Q000378:metabolism; D013940:Thymidylate Synthase / Q000378:metabolism; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000964:Antimetabolites, Antineoplastic; D014408:Biomarkers, Tumor; D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D042943:Dihydrouracil Dehydrogenase (NADP); D013940:Thymidylate Synthase; D009962:Orotate Phosphoribosyltransferase; D013939:Thymidine Phosphorylase